Literature DB >> 35836725

Current Aspects of Treatment Options of Chronic Sialorrhea in Children.

Stefan Bittmann1, Elisabeth Luchter1, Lara Bittmann1, Elena Moschuring-Alieva1, Gloria Villalon1.   

Abstract

Entities:  

Year:  2022        PMID: 35836725      PMCID: PMC9275433          DOI: 10.14740/jocmr4766

Source DB:  PubMed          Journal:  J Clin Med Res        ISSN: 1918-3003


× No keyword cloud information.

To the Editor

Sialorrhea in children is not a primary disease, but the sequela of an existing underlying disease [1-48]. Excessive salivation frequently occurs in children suffering from cerebral palsy (rates between 10% and 58%) [1, 4, 5, 7, 11, 14, 18, 22, 33-35, 39, 40, 42, 43]. This is caused by early brain damage before or at birth or in infancy, which becomes apparent in the first years of life in physical limitations and reduced intelligence [2, 3, 6, 8-10]. Depending on the severity of the disease, the affected children suffer from movement disorders, swallowing difficulties and lack of control over certain muscle groups in the mouth area, among other things [1-49]. Other neurological disorders, such as severe craniocerebral injuries, as well as several developmental disorders can also lead to chronic sialorrhea [1, 4, 5, 7, 11, 14, 18, 22, 33-35, 39, 40, 42, 43]. Hypersalivation refers to a relatively or absolutely excessive flow of saliva, which can lead to wetting of the lips, chin, hands, the surrounding area and to the entry of saliva into the deep airways to varying degrees due to insufficient orofacial abilities and/or a disturbance of sensorimotor control of the swallowing process. This complaint often occurs as an accompanying symptom in patients with a variety of neurological diseases, which may be acute, such as stroke, traumatic brain injury, meningoencephalitis, Guillain-Barre syndrome, critical illness polyneuropathy, and tumors [3, 4, 14]. Nevertheless, autoimmune diseases like multiple sclerosis, myositis and myasthenia, neurodegenerative diseases like amyotrophic lateral sclerosis, Parkinson syndromes as well as muscle diseases lead to hypersalivation [3, 4, 14]. In children, cerebral palsy and several congenital syndromes are associated with sometimes significantly increased salivation [1, 4, 5, 7, 11, 14, 18, 22, 33-35, 39, 40, 42, 43]. The wide range of genesis and the multifactorial aspects of the underlying diseases have led to many studies on the treatment of hypersalivation in recent years, but with little robust evidence. Saliva contains mucin, opiorphin, IgA and haptocorrin and to a highest content of water [6, 7, 9, 12, 34, 35]. Saliva production will be controlled by parasympathetic and sympathetic nerve system. Excessive drooling is pathological at age 4 in childhood [23, 32, 41]. The prevalence ranges around 0.6% and is most often found in despaired children with cerebral palsy or other neurodevelopmental disorders. Saliva production in children is measured in children in a rate up to 1.5 L/day, whereas 3.5 mL/min is defined as hypersalivation, accordingly 5 L/day. Saliva is produced in general in six salivary glands, in two parotid glands, in two submandibular glands and two sublingual glands (both sides included) [1, 3, 5, 6, 9, 14]. In unactivated state, saliva will be produced in submandibular and sublingual glands, whereas in activated state, the parotid glands on both sides play a more important role in producing saliva [1, 8, 9, 26, 41]. Salivary production is normal in newborn, finishes around the 15-18th months of age and is pathological at age 4 [1, 3, 5, 6, 9, 14]. Different subjective scales show different extents of chronic drooling [23, 31, 34, 44]. Risks of chronic drooling in childhood are macerated facial skin, respiratory involvement with aspiration and pneumonia and water imbalance with dehydratation in the child in excessive forms of hypersalivation. Etiological aspects include also anatomical problems, sensory dysfunction, neuromuscular anomalies and hypersecretion. Most important is the impact of sialorrhea on patient’s quality of life [21, 22, 34, 44, 47, 48]. The main focus is on the clarification of swallowing disorders with saliva aspiration and of orofacial motor deficits. Diagnostic procedures include clinical screening examinations as well as: 1) specific ear, nose, and throat (ENT) medical, if necessary, phoniatric examinations of the oral pharynx, the larynx, the swallowing and speech functions, and the internal nose; or 2) in case of neurogenic dysphagia, neurological examinations including fiberoptic endoscopic evaluation of swallowing (FEES). Radiological procedures such as videofluoroscopy can provide important complementary information on the genesis, therapy selection and control. In cases of neurological, traumatic or tumor-therapeutic defect disorders, swallowing-therapeutic exercise measures are indispensable for activating and learning compensatory mechanisms. Therapy is based on a team approach with speech therapists, dentists, otolaryngologists, neurologists, acupuncture and surgery by ENT specialist [1-48]. Algorithm focuses on four different therapy options: non-pharmacological, pharmacological, surgical and radiotherapeutic treatment options [1-48]. Non-pharmacological therapy options are speech-, physio- and orofacial therapy. Pharmacological options to treat sialorrhea are botulinum A/B intra-glandular injections (level A evidence) and anticholinergic treatment like glycopyrronium bromide or transdermal patch therapy with scopolamine (level B evidence) [9, 13, 15, 18-20, 28, 29, 31, 32, 34, 35, 38, 39, 43, 44, 47]. Useful drug therapies for acute hypersalivation include various application forms of glycopyrrolate, of which glycopyrronium bromide received a pan-European pediatric use authorization (PUMA) in 2017 for the symptomatic treatment of hypersalivation in children and adolescents [5]. In recent years, botulinum toxin injections into the major salivary glands have been shown to be an effective and safe treatment modality with long-lasting saliva reduction [9, 13, 15, 18-20, 28, 29, 31, 32, 34, 35, 38, 39, 43, 44, 47]. All anticholinergic medications induce typical side effects like dry mouth, constipation, urinary retention and reduced bronchial secretion. Surgical treatment is based on excision of salivary glands or ligation of salivary ducts. There are many different surgical procedures to curatively treat chronic drooling. The best procedure with highest relief based on a big meta-analysis is bilateral parotid duct ligation and submandibular gland excision. Despite this procedure, four-duct surgical ligation procedure has the lowest success in curative treatment of this rare entity in children [48]. In individual cases, surgical interventions may also be useful by myotomy of the upper esophageal sphincter. Especially in children with hypotonic orofacial muscles, myofunctional therapy concepts are indicated. In addition, oral voice plates as an orthodontic intervention can lead to symptom reduction in the multimodal therapy concept by changing tongue activity and positioning as well as improved lip closure. In conclusion, chronic sialorrhea in children remains a challenge in conservative and surgical treatment, whereas clear guidelines exist but should be temporarily adjusted and optimized due to present knowledge of this serious entity.
  48 in total

Review 1.  Is injection of botulinum toxin type A effective in the treatment of drooling in children with cerebral palsy?

Authors:  L Vaile; F Finlay
Journal:  Arch Dis Child       Date:  2006-10       Impact factor: 3.791

2.  Multidisciplinary management of sialorrhea in children.

Authors:  Sam J Daniel
Journal:  Laryngoscope       Date:  2012-12       Impact factor: 3.325

Review 3.  Interventions for drooling in children with cerebral palsy.

Authors:  Margaret Walshe; Martine Smith; Lindsay Pennington
Journal:  Cochrane Database Syst Rev       Date:  2012-11-14

4.  Four-Duct Ligation for the Treatment of Sialorrhea in Children.

Authors:  Waqas U Khan; Alvi Islam; Ann Fu; Diane C Blonski; Salaha Zaheer; Catherine A McCann; Melissa S Joseph; Rebecca Perlin; Rajab Khan; Paolo Campisi
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2016-03       Impact factor: 6.223

5.  Posterior drooling in children with cerebral palsy and other neurodevelopmental disorders.

Authors:  Corinne Pa Delsing; Stijn Bekkers; Corrie E Erasmus; Karen van Hulst; Frank Ja van den Hoogen
Journal:  Dev Med Child Neurol       Date:  2021-04-12       Impact factor: 5.449

6.  Drooling in children with neurodisability: A survey of Australian speech-language pathologists' practice.

Authors:  Michelle McInerney; Dinah S Reddihough; Paul N Carding; Christine Imms
Journal:  Int J Speech Lang Pathol       Date:  2020-04-15       Impact factor: 2.484

7.  Drooling in cerebral palsy: hypersalivation or dysfunctional oral motor control?

Authors:  Corrie E Erasmus; Karen Van Hulst; Liselotte J C Rotteveel; Peter H Jongerius; Frank J A Van Den Hoogen; Nel Roeleveld; Jan J Rotteveel
Journal:  Dev Med Child Neurol       Date:  2009-02-03       Impact factor: 5.449

Review 8.  Success and complications of four-duct ligation for sialorrhea.

Authors:  W Peyton Shirley; J Scott Hill; Audie L Woolley; Brian J Wiatrak
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2003-01       Impact factor: 1.675

9.  Cost-effectiveness of botulinum neurotoxin A versus surgery for drooling: a randomized clinical trial.

Authors:  Stijn Bekkers; Kim J van Ulsen; Eddy M M Adang; Arthur R T Scheffer; Frank J A van den Hoogen
Journal:  Dev Med Child Neurol       Date:  2020-07-24       Impact factor: 5.449

10.  Treatment of sialorrhea with botulinum toxin A injection in children.

Authors:  E Ture; A Yazar; M A Dundar; S Bakdik; F Akin; S Pekcan
Journal:  Niger J Clin Pract       Date:  2021-06       Impact factor: 0.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.